Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26855513 | 0.88 | PDE9A (0.39) | CXCR2TSHRHPGDNPSR1MTNR1A | |
| SCHEMBL13380074 | 0.88 | PDE9A (0.39) | CXCR2TSHRHPGDNPSR1MTNR1A | |
| SCHEMBL26873972 | 0.88 | PDE9A (0.39) | CXCR2TSHRHPGDNPSR1MTNR1A | |
| SCHEMBL103477 | 0.84 | — | — | |
| SCHEMBL18880078 | 0.84 | SMYD3 (0.47) | SMYD3MTNR1AMTNR1BATMKMT2A | |
| SCHEMBL19135453 | 0.84 | FPR2 (0.39) | FPR2CXCR2TSHRHPGDNPSR1 | |
| SCHEMBL17373709 | 0.84 | SMYD3 (0.39) | FPR2CXCR2TSHRHPGDNPSR1 | |
| SCHEMBL21655188 | 0.84 | FPR2 (0.39) | FPR2CXCR2TSHRHPGDNPSR1 | |
| SCHEMBL19882804 | 0.84 | SMYD3 (0.39) | FPR2CXCR2TSHRHPGDNPSR1 | |
| SCHEMBL29663692 | 0.81 | FPR2 (0.37) | FPR2CXCR2TSHRHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12059420-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024030651-A1 | GPX4 INHIBITORS AND USE THEREOF | SONATA THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| EP-3735404-B1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | SEAL ROCK THERAPEUTICS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| WO-2023109944-A1 | TLR MODULATOR AND USE THEREOF | 映恩生物制药（苏州）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20230145481-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | DICE ALPHA, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230141212-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | DICE ALPHA, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230130516-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-04-27 | — | — | US | disclosed |
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-20120028975-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND ANALOGS THEREOF | SCHERING CORPORATION | 2012-02-02 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| EP-1928236-B1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2011-11-23 | — | — | EP | disclosed |
| US-20110237598-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110002952-A1 | FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-06 | — | — | US | disclosed |
| US-20110002952-A1 | FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-06 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| WO-2006103277-A2 | 2 , 4 , 5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | OAT, GPR119, OTC | FPR2 2198/4885CXCR2 3955/4885TSHR 2009/4885 |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | FPR2 2269/4885CXCR2 2769/4885TSHR 3316/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | FPR2 3648/4885CXCR2 2118/4885TSHR 3456/4885 |
| US-20230145481-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | IL17A, IL2, IL23R | FPR2 552/4885CXCR2 280/4885TSHR 4501/4885 |
| US-12059420-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | FPR2 1272/4885CXCR2 3411/4885TSHR 3230/4885 |
| US-20230130516-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR1, TLR9 | FPR2 176/4885CXCR2 644/4885TSHR 1289/4885 |
| US-20230141212-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | IL17A, IL2, IL23R | FPR2 552/4885CXCR2 280/4885TSHR 4501/4885 |
| US-20120028975-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND ANALOGS THEREOF | PDE2A, PDE5A, PDE4A | FPR2 4189/4885CXCR2 2745/4885TSHR 2271/4885 |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | HDAC10, PDE10A, PDE9A | FPR2 4781/4885CXCR2 3054/4885TSHR 585/4885 |
| US-20110002952-A1 | FUSED HETEROARYL MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF | NFKB2, NFKBIA, AP1G1 | FPR2 300/4885CXCR2 743/4885TSHR 1120/4885 |
| US-20090253689-A1 | Organic Compounds | OAT, GPR119, OTC | FPR2 2198/4885CXCR2 3955/4885TSHR 2009/4885 |
| US-20110237598-A1 | NEW COMPOUNDS | CCNA1, MKI67, CCNE1 | FPR2 1806/4885CXCR2 665/4885TSHR 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.